AB Sciex begins offering ‘breakthrough’ upstream processing tech
The new solution - the CESI-MS - is designed to allow biopharmaceutical scientists to more accurately predict efficacy, reduce the time to market for new therapeutics and proactively detect potential issues before they lead to recalls.
The feedback from clients so far is that this “breakthrough” solution has simplified their upstream processes, Hans Dewald, senior marketing manager of AB Sciex told BioPharma-Reporter.com.
He explained that companies can use the tool to “see all of the analytes in a sample” so then they can look at a number of different factors “in a single run.”
The CESI-MS workflow includes the industry's first commercially available ultra low-flow separation and ESI module for biologics, along with a high-performance, high-resolution, accurate mass instrument.
With a single approach that increases efficiency and productivity, the CESI 8000 system provides orthogonal and/or superior results compared to dual-method liquid chromatography / mass spectrometry-based approaches. From a single digest and run, users of CESI-MS gain:
- Identity and purity information with 100 percent coverage in a peptide map;
- Heterogeneity information with ultrasensitive glycopeptide quantitation; and
- Stability information identifying, deamidation, cyclization and oxidation ‒ all highly important to biopharmaceutical scientists.
“You would start with this in early analytical development, where there’s a large number of samples to run through,” Dewald added. “Separation time is about the same [when compared to other solutions on the market] but you don’t have to run the blanks.”
The CESI 8000, which is manufactured by Beckman Coulter, is an expansion to the CE portfolio within the newly expanded SCIEX Separations. This portfolio also includes the PA 800 plus™pharmaceutical analysis system, the GeXP genetic analyzer and the P/ACE MDQ capillary electrophoresis system.
“Clients want nice glycopeptide coverage…but whether they’ll use this solution depends on where they are in upstream process and what they’re looking for, and if they want to improve workflow,” he added.